Questions discussed in this category
Most would argue that gain(1q) in combination with another high-risk feature constitutes ultra-high-risk multiple myeloma, and most would argue (with ...
The OS benefit with Zometa was seen only in patients with myeloma bone disease achieving less than or equal to a partial response. SRE risk reduction ...
For many clinical trials, a screening bone marrow biopsy is necessary to get a new baseline. Do you do the same in real-world practice?
Previous questions have focused on the newly diagnosed setting and choice of bisphosphonate versus denosumab. IMWG guidelines do recommend resuming zo...
For example - minimum number of months of therapy, driving distance to clinic, at least a CR with or without MRD negativity?
Please assume that IVIG is fine (as it is for many Jehovah's Witness patients, since IgG is often not considered a blood product per se).
Specifically, do you offer closer follow-up for certain patients after local radiation?
Would you do a 24-hour urine and echocardiogram in all of these patients? Cardiac biomarkers, PT/PTT, or any other such blood tests?
Specifically, in the setting of patients that have had a PR or VGPR and are not actively progressing.
This question seems quite specific but happens quite often. Multi-drug chemotherapy runs the risk of profound cytopenias and infections, while bispeci...
Modified HyperCVAD? V(R)D-PACE? DCEP? Are there any data to favor one over the other?
Would you prefer CAR-T or bi-specific or neither? If CAR-T, how do you approach lymphodepletion?
i.e., 60+% bone marrow plasmacytosis, light chain ratio >100, and/or >1 MRI lesion
In addition to reversing hypercalcemia, initiating myeloma therapy, etc.
For example, would you use a tool like the Hydrashift assay? Would this change your management?
1973019619192861957817257189311770018911184111822818114178781772616704171201690216608153151528315509152981492514901
Papers discussed in this category
Br J Haematol, 2021 Aug 15
Blood, 2022 Dec 08
Leukemia, 2019-03
Journal of the American Society of Nephrology : JASN, 2007-03
Lancet Haematol, 2019 Mar 11
Leukemia, 2022 Apr 11
Blood Cancer J, 2022 Sep 02
Cancer, 2021 Jun 28
Leukemia, 2014-03
Lancet Oncol, 2021 Nov 11
Blood, 2022 Oct 20
N Engl J Med, 2023 Jun 05
N Engl J Med, 2023 Jun 05
Br J Haematol, 2023 Jun 07
N Engl J Med, 2023 Feb 10
Experimental hematology & oncology, 2022 Feb 28
The Lancet. Haematology, 2023 Sep 27
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Sep 27
Blood,
N Engl J Med, 2022 Jun 05
J Clin Oncol, 2021 Aug 13
American journal of hematology, 2022 Jul 05
Blood advances, 2023 Oct 24
Blood, 2018 Aug 14
Haematologica, 2013-01
The Lancet. Haematology, 2015 May 06
European respiratory review : an official journal of the European Respiratory Society, 2017 Sep 06
Mayo Clinic proceedings, 2017-06
Blood Cancer J, 2022 Sep 14
The Lancet. Haematology, 2023 Sep 11
The Lancet. Oncology, 2021 Sep 13
The New England journal of medicine, 2019-05-30
Blood, 2023 Nov 30
Cancer, 2011-10-01
BMC Cancer, 2006 May 05
International journal of radiation oncology, biology, physics, 1998-07-15
International journal of radiation oncology, biology, physics, 2006-01-01
Blood, 2014 May 29
Blood, 2014 Jun 17
International journal of radiation oncology, biology, physics, 2011 Jan 27
Leukemia & lymphoma, 2021 Feb 03
Dominion law reports, 1990 Mar 30
American journal of hematology, 2019-04
Blood advances, 2023 Mar 28
American journal of hematology, 2023 Jul 08
Blood, 2013-10-24
The Lancet. Oncology, 2018-03
Blood cancer journal, 2024 Apr 15
Blood cancer journal, 2019 Nov 25
British journal of haematology, 2019 Dec 09
The New England journal of medicine, 2023 Dec 12
Blood cancer journal, 2024 Apr 22